Deepu Madduri, MD, provides an overview of the treatment landscape for patients with triple-class refractory multiple myeloma.
R/R Multiple Myeloma: Review of the CARTITUDE Trial
Rationale regarding the use of BCMA-targeted CAR T-cell therapy in relapsed/refractory multiple myeloma.
Clinical updates from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.
A review of the favorable safety data from CARTITUDE-1 for relapsed/refractory multiple myeloma.
Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.
Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
